Claims:

1. A method of treating a hematological malignancy comprising administering to a subject in need thereof an effective amount of (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof and an effective amount of venetoclax or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the method comprises administering (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof sequentially, separately or simultaneously with venetoclax or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 or 2, wherein the hematological malignancy is selected from acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML), chronic lymphocytic leukaemia (CLL), and chronic myelomonocytic leukemia (CMML).

4. (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof for use in the treatment of a hematological malignancy, wherein the treatment comprises separate, sequential or simultaneous administration of venetoclax or a pharmaceutically acceptable salt thereof.

5. Venetoclax or a pharmaceutically acceptable salt thereof for use in the treatment of a hematological malignancy, wherein the treatment comprises separate, sequential or simultaneous administration of (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof.

6. The use of claim 4 or 5, wherein the hematological malignancy is selected from acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML), chronic lymphocytic leukaemia (CLL), and chronic myelomonocytic leukemia (CMML).

7. The method or use of any one of claims 1 to 6, which further comprises administering an effective amount of 5-azacitidine.

8. The method or use of claim 3 or 6, wherein the hematological malignancy is a relapsed or refractory hematological malignancy.

9. The method or use of claim 3 or 6, wherein the hematological malignancy is resistant to a monotherapy of a BCL-2 inhibitor.

10. A kit comprising:

a first pharmaceutical composition comprising (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier; and

a second pharmaceutical composition comprising venetoclax or a pharmaceutically acceptable salt thereof and instructions for use.

11. The kit of claim 10, which further comprises a third pharmaceutical composition comprising 5-azacitidine.

12. A pharmaceutical product comprising i) (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof, and ii) venetoclax or a pharmaceutically acceptable salt thereof.

13. The pharmaceutical product of claim 1, wherein (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof and venetoclax or a pharmaceutically acceptable salt thereof are present in a single dosage form.

14. The pharmaceutical product of claim 1, wherein (*3R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof and venetoclax or a pharmaceutically acceptable salt thereof are present in separate dosage forms.